Park Ha Biological Technology Co., Ltd. (the “Company”), a firm specializing in private skincare labels, direct sales, and franchise partnerships, announced the pricing of its initial public offering (IPO) of 1,200,000 ordinary shares at $4.00 per share. These shares are slated for listing on the Nasdaq Capital Market, commencing trading on December 27, 2024, under the ticker symbol “PHH.”
The Company anticipates gross proceeds of $4.8 million from the IPO, before accounting for underwriting discounts and expenses. A 45-day option to purchase up to an additional 180,000 shares at the offering price (less discounts) has been granted to underwriters. The offering is projected to close around December 30, 2024, contingent upon customary closing conditions.
Net proceeds will fund expansion of directly-owned stores in China, acquisition of existing product patents for proprietary product development, and the acquisition of ingredient suppliers to achieve long-term cost reductions.
Dawson James Securities, Inc. and D. Boral Capital LLC acted as underwriters for the firm commitment offering. Ortoli Rosenstadt LLP serves as U.S. securities counsel for the Company, and Hunter Taubman Fischer & Li LLC for the Underwriters.
A Form F-1 registration statement (File Number: 333-281783) was filed with and declared effective by the U.S. Securities and Exchange Commission (SEC) on December 20, 2024. The offering is solely via prospectus, part of the registration statement. Prospectuses are available from Dawson James Securities, Inc. (mail: 101 N. Federal Highway Suite 600 Boca Raton, Florida 33432; email: [redacted]; phone: +1(561)-391-5555) or D. Boral Capital LLC (mail: 590 Madison Ave 39th Floor, New York, NY 10022; email: [redacted]; phone: +1(212)-970-5150), and on the SEC website at [redacted].
Review the prospectus and SEC filings before investing. This release is for informational purposes only and does not constitute an offer to sell or solicitation of an offer to buy securities where prohibited by law.
About Park Ha Biological Technology Co., Ltd.
Founded in 2016, Park Ha Biological Technology Co., Ltd. focuses on its private skincare label, direct sales, and franchise partnerships under the “Park Ha” brand, aiming to provide cost-effective skincare solutions. As of April 30, 2024, the Company operated two directly owned stores and 43 franchisees (41 “Park Ha” and two “Geni” branded) in China, offering complimentary “light beauty experience” after-sales service. Visit [redacted] for more details.
Forward-Looking Statements
This announcement contains forward-looking statements, including regarding the IPO. These statements involve risks and uncertainties and are based on current expectations. Words like “approximates,” “believes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may,” and similar expressions often identify forward-looking statements. The Company is not obligated to update these statements, except as required by law. Actual results may differ materially; review the Company’s registration statement and SEC filings for more information.
For more information, please contact:
Park Ha Biological Technology Co., Ltd.
Investor Relations Department
Email: [redacted]
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: [redacted]
